アブストラクト
Japanese
| Title | 第14章 主な抗喘息薬一覧表 |
|---|---|
| Subtitle | ガイドライン解説 : 小児気管支喘息治療・管理ガイドライン2020 |
| Authors | 山田佳之1), 足立雄一2) |
| Authors (kana) | |
| Organization | 1)東海大学医学部総合診療学系小児科学, 2)富山大学学術研究部医学系小児科講座 |
| Journal | 日本小児アレルギー学会誌 |
| Volume | 36 |
| Number | 2 |
| Page | 175-178 |
| Year/Month | 2022 / |
| Article | 報告 |
| Publisher | 日本小児アレルギー学会 |
| Abstract | 「抄録」 : 日本小児アレルギー学会による「小児気管支喘息治療・管理ガイドライン」 (以下JPGL) の普及により, 小児気管支喘息診療の均てん化がすすみ, 小児気管支喘息治療の基本薬剤が適切に使用されるようになってきている. 第14章では主な抗喘息薬について一覧表にして示した. 主要な薬剤はこれまでと大きな変化はないが, JPGL2017に比べ生物学的製剤についての情報が追加・更新された. 具体的にはメポリズマブの適用年齢が6歳以上となり, 新たにデュピルマブが12歳以上の適用となった. また吸入ステロイド薬・β2刺激薬配合剤であるフルチカゾンプロピオン酸エステル・ホルモテロールフマル酸塩水和物配合剤に小児適用が追加された. 全体として, JPGL2017と同様に独立行政法人医薬品医療機器総合機構 (PMDA) から得られる薬剤情報をもとに表を作成し, 禁忌, 副作用については別項目として記載した. 本稿では一覧表に記載された主な薬剤についてJPGL2020本文中で議論された内容も引用し解説した. |
| Practice | 臨床医学：内科系 |
| Keywords | 生物学的製剤, デュピルマブ, メポリズマブ, オマリズマブ, 小児喘息, biologics, dupilumab, mepolizumab, omalizumab, pediatric bronchial asthma |
English
| Title | Chapter 14 : List of principal anti-asthmatic agents |
|---|---|
| Subtitle | |
| Authors | Yoshiyuki Yamada1), Yuichi Adachi2) |
| Authors (kana) | |
| Organization | 1)Department of Pediatrics, Tokai University School of Medicine, 2)Department of Pediatrics, Faculty of Medicine, University of Toyama |
| Journal | The Japanese Journal of Pediatric Allergy and Clinical Immunology |
| Volume | 36 |
| Number | 2 |
| Page | 175-178 |
| Year/Month | 2022 / |
| Article | Report |
| Publisher | Japanese Society of Pediatric Allergy and Clinical Immunology |
| Abstract | [Summary :] The popularization of the Japanese Pediatric Guideline for the Treatment and Management of Bronchial Asthma (JPGL) has enabled standardization of the approach to pediatric bronchial asthma. This has resulted in the appropriate use of basic anti-asthmatic drugs for children. In chapter 14 of the JPGL 2020, the principal therapeutic agents for pediatric bronchial asthma are listed. These medications have remained almost unchanged over recent years except for updates on the information on biologics since JPGL 2017. In particular, the age of insurance coverage for use of mepolizumab has been lowered to at least 6 years and dupilumab has been newly approved for use in children over 12 years old. In addition, fluticasone propionate/formoterol fumarate hydrate has become available for children over 6 years of age. As with JPGL 2017, the table in chapter 14 was prepared based on the information obtained from the Pharmaceuticals and Medical Devices Agency. The contraindications and adverse reactions of these drugs are described separately. This article presents a brief discussion of the principal anti-asthmatic agents listed in chapter 14, by quoting the interpretations provided in the main text of JPGL 2020. |
| Practice | Clinical internal medicine |
| Keywords | biologics, dupilumab, mepolizumab, omalizumab, pediatric bronchial asthma |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 独立行政法人医薬品医療機器総合機構(PMDA). https://www.pmda.go.jp/PmdaSearch/iyakuSearch/
- 2) Chauhan B. F., et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2015 ; CD007949.
- 3) Stempel D. A., et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med 2016 ; 375 : 840-849.
- 4) (GINA)Global Initiative for Asthma. 2019 GINA main report. Global Strategy for Asthma Manage-ment and Pre-vention 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
- 5) 久米裕昭, 他. β2刺激薬の固有活性とそれに基づく臨床投与の実際. アレルギー・免疫 2009 ; 16 : 1604-1614.
残りの3件を表示する
- 6) Nalin U., Stout S., Portnoy J. M.. Single inhaler maintenance and reliever therapy in pediatric asthma. Curr Opin Allergy Clin Immunol 2019 ; 19 : 111-117.
- 7) Brodlie M., et al. Leukotriene receptor antago-nists as maintenance and intermittent therapy for episodic viral wheeze in children. Cochrane Database Syst Rev 2015 ; CD008202.
- 8) Katsunuma T., et al. Low-dose l-isoproterenol ver-sus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma : A double-blind, randomized controlled trial. Allergol Int 2019 ; 68 : 335-341.
